Sign in

Specific Biologics

Series A · $35M · November 2026 · Biotech & pharma · Other regions

What it sells

Develops Dualase genome editors as in vivo gene-editing medicines; announced a US$35M Series A to advance a gene-editing therapy for ALS.

Funding history and coverage

Round dateStageAmountInvestorsSource
2026-11-04Series A$35MHatteras Venture Partners (lead)pulse2.com
2026-11-02Series A$35M—prnewswire.com

Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-11-10.

More startups in Biotech & pharma

  1. Kardi Ai

    Kardi Ai is a non-invasive, reusable single-lead ECG medical device for adults that records and analyses the heart's electrical activity, for home or clinical use, detecting…

    Series A · €5.3M · 2026-11-11Biotech & pharmaEurope

  2. Switchpoint Bio

    Switchpoint Bio combines blood-based epigenomics (DNA methylation) and AI to produce decision-grade evidence for drug development: biomarker discovery, patient stratification and…

    $5.3M · 2026-11-11Biotech & pharmaEurope

  3. SRTD Biotech

    Cell-selective mRNA therapeutics: seRNA constructs are delivered inactive and switch on only when they detect a disease-specific RNA inside the target cell, found by an AI…

    Seed · €31.5M · 2026-11-10Biotech & pharmaEurope

  4. Lucidome Bio

    Lucidome Bio is developing a vaccine that triggers antibodies against methanogens in the rumen to cut methane emissions from cattle and other ruminant livestock, including…

    $9M · 2026-11-10Biotech & pharmaAsia

  5. Efferon

    Efferon makes CE-marked multimodal hemoadsorption devices (Efferon LPS for adults, Efferon NEO for children) that remove endotoxin and cytokines from the blood to treat sepsis…

    Seed · €4.3M · 2026-11-10Biotech & pharmaEurope

  6. Oyster Therapeutics

    Develops targeted protein degrader therapeutics using its SELFTAC platform, where two small molecules cross biological barriers and self-assemble into a full degrader. First…

    Series A-2 · $60M · 2026-11-10Biotech & pharmaOther regions

All startups in this market →